Skip to main content
Premium Trial:

Request an Annual Quote

Erasmus Uses Ingenuity for NGS Data

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Erasmus University Medical Center in the Netherlands is using Ingenuity Systems’ software in its next-generation sequencing-based disease and compound studies under a collaboration announced by Ingenuity today.

Erasmus is using Ingenuity’s IPA software and its Knowledge Base and is working with the company to help map and study genes and variants linked to biological processes, functions, diseases, pathways, compounds, and relationships in order to obtain "a more complete biological picture from their NGS data," the company said.

"Like many researchers, we faced the challenge of sifting through thousands of variants in order to rapidly identify the few that were the best candidates for follow-up studies and those most likely to be causal for our disease phenotype," EUMC Professor Peter van der Spek said in a statement.

"IPA helped us overcome this challenge and discover a novel causal variant in a disease area of interest. It provides the critical biological context necessary to realize the full potential of NGS datasets,” van der Spek added.

Financial terms of the agreement were not released.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.